NCT06190145View on ClinicalTrials.gov

Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 5, 2023

Primary Completion Date

October 15, 2024

Study Completion Date

June 15, 2025

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Teriflunomide

Starting dose of 7 mg once daily. Dose adjustments were made throughout the study based on individual platelet counts.

Trial Locations (1)

Unknown

RECRUITING

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER